- Home
- VRAR vs BOLD Comparison
VRAR vs BOLD Comparison
Compare VRAR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- BOLD
- Stock Information
- Founded
- VRAR 2016
- BOLD 2018
- Country
- VRAR United States
- BOLD United States
- Employees
- VRAR N/A
- BOLD N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- BOLD
- Sector
- VRAR Technology
- BOLD
- Exchange
- VRAR Nasdaq
- BOLD Nasdaq
- Market Cap
- VRAR 33.3M
- BOLD 24.4M
- IPO Year
- VRAR 2021
- BOLD 2024
- Fundamental
- Price
- VRAR $1.49
- BOLD $1.17
- Analyst Decision
- VRAR Strong Buy
- BOLD Buy
- Analyst Count
- VRAR 1
- BOLD 3
- Target Price
- VRAR $2.62
- BOLD $4.00
- AVG Volume (30 Days)
- VRAR 135.2K
- BOLD 286.6K
- Earning Date
- VRAR 05-15-2025
- BOLD 08-11-2025
- Dividend Yield
- VRAR N/A
- BOLD N/A
- EPS Growth
- VRAR N/A
- BOLD N/A
- EPS
- VRAR N/A
- BOLD N/A
- Revenue
- VRAR $8,756,789.00
- BOLD N/A
- Revenue This Year
- VRAR $23.96
- BOLD N/A
- Revenue Next Year
- VRAR $12.15
- BOLD N/A
- P/E Ratio
- VRAR N/A
- BOLD N/A
- Revenue Growth
- VRAR N/A
- BOLD N/A
- 52 Week Low
- VRAR $0.50
- BOLD $1.00
- 52 Week High
- VRAR $7.00
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- VRAR 52.95
- BOLD N/A
- Support Level
- VRAR $1.31
- BOLD N/A
- Resistance Level
- VRAR $1.38
- BOLD N/A
- Average True Range (ATR)
- VRAR 0.11
- BOLD 0.00
- MACD
- VRAR 0.01
- BOLD 0.00
- Stochastic Oscillator
- VRAR 66.67
- BOLD 0.00
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.